ERBB2 and breast carcinoma: Immunohistochemistry (IHC) and a breast cancer cell line microarray revealed that ADAM8 was present in approximately one-third of breast cancers, with high levels linked to adverse outcomes in hormone receptor-positive/HER2-negative subtypes [64,65].